388 related articles for article (PubMed ID: 26870930)
21. In search of the magic bullet: can liver inflammation and fibrosis be reversed with medications?
Zimmermann HW; Tacke F
Expert Rev Gastroenterol Hepatol; 2015; 9(9):1139-41. PubMed ID: 26138749
[TBL] [Abstract][Full Text] [Related]
22. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis.
Lambrecht J; van Grunsven LA; Tacke F
Expert Opin Pharmacother; 2020 Sep; 21(13):1637-1650. PubMed ID: 32543284
[TBL] [Abstract][Full Text] [Related]
23. Naringenin reduces cholesterol-induced hepatic inflammation in rats by modulating matrix metalloproteinases-2, 9 via inhibition of nuclear factor κB pathway.
Chtourou Y; Fetoui H; Jemai R; Ben Slima A; Makni M; Gdoura R
Eur J Pharmacol; 2015 Jan; 746():96-105. PubMed ID: 25446569
[TBL] [Abstract][Full Text] [Related]
24. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target?
Dongiovanni P; Rametta R; Meroni M; Valenti L
Expert Rev Gastroenterol Hepatol; 2016; 10(2):229-42. PubMed ID: 26641143
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis.
Li YH; Yang LH; Sha KH; Liu TG; Zhang LG; Liu XX
World J Gastroenterol; 2015 Jun; 21(22):7008-13. PubMed ID: 26078579
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Landscape for NAFLD in 2020.
Neuschwander-Tetri BA
Gastroenterology; 2020 May; 158(7):1984-1998.e3. PubMed ID: 32061596
[TBL] [Abstract][Full Text] [Related]
27. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis.
Shi YW; Fan JG
Acta Pharmacol Sin; 2022 May; 43(5):1191-1199. PubMed ID: 34907360
[TBL] [Abstract][Full Text] [Related]
28. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.
Noureddin M; Anstee QM; Loomba R
Aliment Pharmacol Ther; 2016 Jun; 43(11):1109-23. PubMed ID: 27061197
[TBL] [Abstract][Full Text] [Related]
29. Treatment of experimental non-alcoholic steatohepatitis by targeting α7 nicotinic acetylcholine receptor-mediated inflammatory responses in mice.
Zhou Z; Liu YC; Chen XM; Li FQ; Tong XJ; Ding YP; Tang CL
Mol Med Rep; 2015 Nov; 12(5):6925-31. PubMed ID: 26397391
[TBL] [Abstract][Full Text] [Related]
30. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
31. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
[TBL] [Abstract][Full Text] [Related]
32. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
33. Preventing liver fibrosis in patients with NAFLD and the road ahead.
Nobili V; Miele L; Alisi A
Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1081-1083. PubMed ID: 28994314
[No Abstract] [Full Text] [Related]
34. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
Ding Y; Sun X; Chen Y; Deng Y; Qian K
Eur J Pharmacol; 2015 Aug; 761():405-12. PubMed ID: 25967348
[TBL] [Abstract][Full Text] [Related]
35. Human-based systems: Mechanistic NASH modelling just around the corner?
Boeckmans J; Natale A; Buyl K; Rogiers V; De Kock J; Vanhaecke T; Rodrigues RM
Pharmacol Res; 2018 Aug; 134():257-267. PubMed ID: 29964161
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptor α, a potential therapeutic target for alcoholic liver disease.
Nan YM; Wang RQ; Fu N
World J Gastroenterol; 2014 Jul; 20(25):8055-60. PubMed ID: 25009377
[TBL] [Abstract][Full Text] [Related]
37. Effect of resveratrol on experimental non-alcoholic steatohepatitis.
Heebøll S; Thomsen KL; Clouston A; Sundelin EI; Radko Y; Christensen LP; Ramezani-Moghadam M; Kreutzfeldt M; Pedersen SB; Jessen N; Hebbard L; George J; Grønbæk H
Pharmacol Res; 2015; 95-96():34-41. PubMed ID: 25814186
[TBL] [Abstract][Full Text] [Related]
38. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
Lee HJ; Yeon JE; Ko EJ; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Lee BJ; Kim JH; Seo YS; Yim HJ; Byun KS
World J Gastroenterol; 2015 Dec; 21(45):12787-99. PubMed ID: 26668503
[TBL] [Abstract][Full Text] [Related]
39. Flame Retardants-Mediated Interferon Signaling in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Negi CK; Khan S; Dirven H; Bajard L; Bláha L
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924165
[TBL] [Abstract][Full Text] [Related]
40. Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators.
Serhal R; Hilal G; Boutros G; Sidaoui J; Wardi L; Ezzeddine S; Alaaeddine N
Biomed Res Int; 2015; 2015():850246. PubMed ID: 26273651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
